• Share
  • Email
  • Print

Virginia Tam

Partner
+852.2230.3535
Fax +852.2511.9515
Ms. Tam focuses on outbound acquisitions and private equity investments for corporate and financial institution clients in Greater China. A lawyer experienced in U.S. securities laws and Hong Kong Listing Rules, Ms. Tam has worked on a broad range of matters within this practice area, including private and public acquisitions, private investment in publicly-traded equities (PIPEs), pre-IPO investments, joint ventures, capital market exits and privatizations.

Ms. Tam has been recognized for her legal expertise by Asia Pacific Legal 500 for her work in China Corporate and M&A.

Professional Background

Prior to joining K&L Gates, Ms. Tam was a partner in the Hong Kong office of another American law firm.

Professional/Civic Activities

Ms. Tam is a member of the firm’s pro bono committee and women-in-profession committee.

Speaking Engagements

Ms. Tam has spoken extensively on mergers and acquisitions, private equity and PIPEs and is a regular moderator and panelist at conferences on corporate finance and mergers and acquisitions.
Public and Private Acquisitions
  • Advising TCL Industries Holdings (HK) Limited, the parent of a HKSE-listed telecommunications equipment manufacturer, in the acquisition of the MiFi business of Novatel Wireless, Inc., a Nasdaq-listed company, for US$50 million in cash.
  • Advising Up Energy Development Group Limited, an HKSE-listed PRC coal mining company, in the acquisition of Grande Cache Coal, a Canadian coal producer, from Winsway Enterprises Holdings Limited, an HKSE-listed company, and Marubeni Corporation, a Japan-listed company, and the provision of US$73 million in interim financing to Grande Cache Coal.
  • Advising a consortium of Taiwan shareholders in the privatization of Actions Semiconductor Inc., a Nasdaq-listed PRC provider of integrated platform solutions for IoT devices.
  • Advising the special committee of the board of directors of 21Vianet Group, Inc., a Nasdaq-listed PRC internet data center services provider, in the privatization of 21Vianet Group by a consortium led by its controlling shareholder, Kingsoft Co. Ltd. and Tsinghua Unigroup International Co. Ltd.
  • Advising Chinanx Financial Group, a PRC investment group, in its strategic investment in NordAq, Inc., a U.S. oil and gas developer, for up to US$90 million in cash.
  • Advising a consortium led by Leadyond Capital, a PRC private equity fund, in the privatization of Wonder Auto Technology Group, Inc. a Nasdaq-listed PRC automobile parts manufacturer.
  • Advising China Donxiang (Group) Co., Ltd., an HKSE-listed sportswear brand enterprise in the PRC, in its all cash acquisition of Point Roberts Resort Marina in Washington, the United States. 
  • Advising China International Mining Group Corporation, a Hong Kong conglomerate consisting of industry veterans, in its acquisition of a substantial interest in Mwana Africa plc, a UK-listed Africa metals mining company, and a subsequent proxy fight for corporate control.
  • Advising the special committee of the board of directors of Exceed Company Limited, a Nasdaq-listed PRC sportswear manufacturer and distributor, in a privatization by a consortium led by its controlling shareholder.
  • Advising a PRC project fund in its strategic investment in AP International Limited (Hong Kong), a manufacturer focusing on the design, development and production of optical and opto-mechanical products.

Pre-IPO and PIPE Transactions
  • Advising Shenzhen Blue Ocean Development Fund Management Company, as general partner, and its affiliated funds in a US$250 million investment in the privatization of China Cord Blood Corporation, an NYSE-listed cord blood banking business, by Golden Meditech Holdings Limited, an HKSE-listed healthcare company.
  • Advising Perfect World Pictures Co., Limited, a PRC-listed motions picture producer, in a US$60 million pre-IPO investment in China Fortran Media Group, a PRC media marketing services provider, prior to its application for listing on the HKSE.
  • Advising CCB International Asset Management Limited in a HK$230 million pre-IPO investment in Power Wealth Investment Holdings Limited, one of the largest dredging companies in China, and subsequent restructurings following Power Wealth’s HK IPO.
  • Advising veteran Hong Kong investors in their investment in ChinaBiomedicine Group Inc., a Nasdaq-listed PRC cellular therapy solutions developer.
  • Advising Up Energy Group Ltd, as controlling shareholder, in a US$120 million private equity financing and a US$175 million placement of convertible bonds of Up Energy Development Group Limited, an HKSE-listed PRC coal mining company, to institutional and strategic investors.
  • Advising CCB International Asset Management Limited in its HK$233 million subscription of convertible bonds and warrants from Mingyuan Medicare Development Company Limited, an HKSE-listed PRC medical solutions provider, with Citigroup Global Markets Asia Limited acting as the placement agent.
  • Advising China International Mining Group Corporation, a Hong Kong conglomerate consisting of industry veterans, in its PIPE investment in Universal Coal plc, an Australia-listed Africa coal mining company.
  • Advising Essence International Investment Limited in its subscription of convertible notes and warrants from China Biologic Products, Inc., a Nasdaq-listed PRC biopharmaceutical product manufacturer; and subsequent resale of a portion of the shares to Warburg Pincus.

Private Equity and Mezzanine Debt Transactions
  • Advising China Development Bank International Holdings Limited in its US$130 million private equity investment in the spin-off of the China business of Global Logistic Properties, a Singapore-listed warehouse operator.
  • Advising China Development Bank International Holdings Limited, as private equity investor, in the privatization of Zhongpin Inc., a Nasdaq-listed PRC pork producer.
  • Advising China Development Bank International Holdings Limited, as private equity investor, in the privatization of China Transinfo Technology Corp., a NYSE-listed PRC technology solutions provider.
  • Advising Windrace International Company Limited, a PRC sportswear manufacturer and distributor, in its HK$315 million redemption of preferred shares from Goldman Sachs using proceeds of a share placement to New Horizon Capital.
  • Advising Up Energy Group Ltd. in a US$75 million secured exchangeable loan financing from a leading investment bank as part of its business combination with Tidetime Sun (Group) Limited, an HKSE-listed company.
  • Advising the controlling shareholder of an HKSE-listed company in its HK$669 million acquisition of a substantial interest in a PRC-listed company through a capital restructuring between the two companies.
  • Advising Pacific Alliance Group, as arranger, in a US$120 million exchangeable term loan financing for Kaisa Group Holdings Limited, an HKSE-listed PRC property developer.
  • Advising a leading investment bank, as arranger, in a US$250 million loan and private equity financing for a major shareholder of an HKSE-listed company.

Capital Markets Exits
  • Advising China Cord Blood Services Corporation in its US$318 million business combination with Pantheon China Acquisition, an Amex-listed special purpose acquisition company, and NYSE listing.
  • Advising Windrace International Company Limited, a manufacturer and wholesaler of footwear and apparel in China, in its US$133.5 million business combination with 2020 Chinacap Acquirco, Inc., an Amex-listed special purpose acquisition company, and Nasdaq listing.
  • Advising Golden Meditech Company Limited in its HK$436 million sale of American depositary shares of China Medical Technologies, a Nasdaq-listed PRC medical device manufacturer and distributor in a U.S. public offering.
  • Advising Essence International Investment Limited in its US$60 million sale of shares of China Biologic Products, Inc., a Nasdaq-listed PRC biopharmaceutical product manufacturer, in a U.S. public offering.
  • Advising China Development Bank International Holding Limited, as private equity investor, in the privatization of Zhongpin Inc., a Nasdaq-listed PRC biopharmaceutical product manufacturer, in a U.S. public offering.